Redox mediating epigenetic changes confer metabolic memories

Circulation Research

Volumn 111, Issue 3, 2012, Pages 262-264

  El Osta, Assam ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METHYLGLYOXAL; METHYLTRANSFERASE; PROTEIN KINASE C BETA; PROTEIN P66; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; SUPEROXIDE;

BLOOD VESSEL; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; DISEASE COURSE; DNA METHYLATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPIGENETICS; EXPERIMENTAL ANIMAL; GENE ACTIVATION; GENE EXPRESSION; GENETIC REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCATION; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; STREPTOZOCIN DIABETES; UPREGULATION; VASCULAR DISEASE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GENE SILENCING; HUMANS; HYPERGLYCEMIA; MALE; MITOCHONDRIA; SHC SIGNALING ADAPTOR PROTEINS;

EID: 84864188555     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.274936     Document Type: Review

References (22)

1. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986;35:530-545.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993;329:977-986.
3. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999;22:99-111.
4. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
5. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003; 290:2159-2167.
6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353: 2643-2653. (Pubitemid 41817713)
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
8. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-812. (Pubitemid 17145301)
9. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87:404-408.
10. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409-2417.
11. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, El-Osta A. Distinguishing hyperglycemic changes by set7 in vascular endothelial cells. Circ Res. 2012;110:1067-1076.
12. Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren B, Natarajan R. Role of the histone h3 lysine 4 methyltransferase, set7/9, in the regulation of NF-kappab-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem. 2008;283:26771-26781.
13. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes. 2011;60:1304-1313.
14. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. (Pubitemid 34000785)
15. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790. (Pubitemid 30212409)
16. Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, LuÂ̈scher TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66Shc suppresses vascular hyperglycemic memory in diabetes. Circ Res. 2012;112:278-289.
17. Giorgio M, Migliaccio E, Orsini F, et al. Electron transfer between cytochrome c and p66shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122:221-233. (Pubitemid 41032986)
18. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, Leitges M, Menne J, Haller H. Deletion of protein kinase c-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocininduced diabetic mouse model. Diabetes. 2007;56:346-354.
19. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral pkc beta inhibitor. Science. 1996;272:728-731. (Pubitemid 26000279)
20. Pirola L, Balcerczyk A, Tothill RW, et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res. 2011;21:1601-1615.
21. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070.
22. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010;107:1403-1413.